33 patents
Page 2 of 2
Utility
Formulations and Doses of Pegylated Uricase
23 Dec 20
Provided herein are methods and compositions and kits related to identification and/or treatment of subjects, including subjects with hyperuricemia, gout or a condition associated with gout, and for preventing gout flare.
Lloyd Johnston, Takashi Kei Kishimoto, Earl Sands, Werner Cautreets
Filed: 3 Jun 20
Utility
Nanocarriers Possessing Components with Different Rates of Release
16 Dec 20
This invention relates to compositions, and related methods, of synthetic nanocarriers that comprise immunomodulatory agents and antigens that are differentially released from the synthetic nanocarriers.
Grayson B. Lipford, Charles Zepp, Yun Gao, Mark J. Keegan, Sam Baldwin, Fen-ni Fu, Lloyd Johnston
Filed: 26 Jan 20
Utility
Methods and Compositions for Attenuated Anti-viral Transfer Vector Immune Response
16 Dec 20
Provided herein are methods and related compositions or kits for administering viral transfer vectors in combination with synthetic nanocarriers comprising an immunosuppressant and a corticosteroid.
Takashi Kei Kishimoto, Petr Ilyinskii
Filed: 27 May 20
Utility
Methods for Treatment of Subjects with Preexisting Immunity to Viral Transfer Vectors
18 Nov 20
Provided herein are methods and related compositions for administering viral vectors with synthetic nanocarriers comprising an immunosuppressant to subjects.
Takashi Kei Kishimoto, Petr Ilyinskii
Filed: 27 Apr 20
Utility
Tolerogenic Synthetic Nanocarriers to Reduce or Prevent Anaphylaxis In Response to a Non-allergenic Antigen
18 Nov 20
This invention relates to methods for reducing or preventing anaphylaxis to non-allergenic antigens with compositions comprising immunosuppressants, and related compositions.
Roberto A. Maldonado
Filed: 23 Apr 20
Utility
Methods Related to Administering Immunosuppressants and Therapeutic Macromolecules at a Reduced Pharmacodynamically Effective Dose
15 Apr 20
Disclosed are compositions and methods that provide pharmacodynamic effects specific to therapeutic macromolecules.
Roberto A. Maldonado, Takashi Kei Kishimoto
Filed: 25 Aug 19
Utility
Tolerogenic Synthetic Nanocarriers for Antigen-specific Deletion of T Effector Cells
1 Apr 20
Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion).
Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
Filed: 7 Aug 19
Utility
Tolerogenic Synthetic Nanocarriers for Generating CD8+ Regulatory T Cells
1 Apr 20
Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells.
Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
Filed: 3 Sep 19
Utility
Methods Providing a Therapeutic Macromolecule and Synthetic Nanocarriers Comprising Immunosuppressant Locally and Concomitantly to Reduce Both Type 1 and Type IV Hypersensitivity
11 Mar 20
Disclosed are methods and related compositions for concomitantly, locally administering immunosuppressants and doses of therapeutic macromolecules for reducing Type I and Type IV hypersensitivity.
Roberto A. Maldonado
Filed: 10 Jun 19
Utility
Methods of Administering Immunosuppressants Having a Specified Pharmacodynamic Effective Life and Therapeutic Macromolecules for the Induction of Immune Tolerance
4 Mar 20
This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules.
Takashi Kei Kishimoto
Filed: 12 May 19
Utility
Methods Comprising Dosing Combinations for Reducing Undesired Humoral Immune Responses
4 Mar 20
Disclosed are dosings of therapeutic macromolecules and immunosuppressants, in some embodiments attached to synthetic nanocarriers, in combination with dosings of therapeutic macromolecules without synthetic nanocarriers, and related methods that provide reduced humoral immune responses.
Roberto A. Maldonado, Takashi Kei Kishimoto
Filed: 5 Jun 19
Utility
Methods and Compositions of Otc Constructs and Vectors
5 Feb 20
Provided herein are methods and compositions related to nucleic acids encoding ornithine transcarbamylase (OTC), such as nucleic acids comprising an OTC codon-optimized sequence, as well as related vectors, such as AAV vectors.
Peter Keller, Takashi Kei Kishimoto, Andres Muro, Giulia De Sabbata
Filed: 15 Jul 19
Utility
Methods and Compositions of Mma Constructs and Vectors
5 Feb 20
Provided herein are methods and compositions related to nucleic acids encoding methylmalonyl-CoA mutase (MUT) as well as related vectors, such as AAV vectors and Anc80 vectors.
Peter Keller, Takashi Kei Kishimoto
Filed: 15 Jul 19